Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOCIDEX: Tocilizumab + Dexamethasone for COVID-19
NCT04476979Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2020
- Primary completion
- Jun 2021
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tocilizumab in COVID-19 pneumonia, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Survival without needs of invasive ventilation at day 14. Started Jul 2020; status: completed.
02
Drugs
tocilizumab
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04476979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04476979.